Trial Profile
A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 22 Jun 2017 Status changed from completed to discontinued.
- 06 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016.